secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paysign, Inc. (PAYS)
CIK:        0001496443
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001683168-24-007620
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Paysign Q3 revenue up 23% to $15.26M; pharma affordability revenue surges 219%
------------------------------------------------------------------------------

- Total revenues $15.26M (+23% YoY); net income $1.44M ($0.03 diluted EPS) vs $1.10M ($0.02) prior year.
- Pharma patient affordability revenue surged 219.1% YoY, now 21.5% of total revenue; 66 active programs at quarter end.
- Adjusted EBITDA $2.83M (+20.6% YoY); FY2024 guidance reaffirmed: rev $56.5-58.5M, adj. EBITDA $9-10M.
- Plasma revenue up 3.4% YoY from 478 centers; average monthly revenue per center $7,991, down slightly from $8,041.
- Unrestricted cash $10.29M, zero debt; Q4 legal expense expected for class action settlement but within guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496443/000168316824007620/0001683168-24-007620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496443/000168316824007620/paysign_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-007620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer